MARA Renewables Corporation

Mara is a Canadian biotechnology company headquartered in Atlantic Canada, specializing in the production of fish-free, algae-derived Omega-3 fatty acids for use across multiple market segments including infant formula, nutritional supplements, functional food and beverage, and animal nutrition. The company has isolated a novel marine microalgal strain native to the shores of Atlantic Canada that naturally produces DHA-rich Omega-3 fatty acids, enabling a vertically integrated, back-integrated production process that eliminates reliance on fish oil as a raw material source.

Mara's algal oil portfolio spans refined oils, concentrates, softgels, and powdered formats, giving B2B customers flexibility in how they incorporate DHA into finished products. All products are vegetarian, solvent-free, and free from marine contaminants. The company's manufacturing process is FSSC 22000 accredited and operates within a fully enclosed and controlled environment, ensuring consistent quality and food safety. Products carry Halal and Kosher certifications, broadening their appeal across global consumer markets.

A key application for Mara's algal DHA oil is infant and toddler formula, where DHA plays a critical role in early brain, eye, bone, and nervous system development. The company's algal oil has received European approval for use in infant formula, as well as GRAS (Generally Recognized as Safe) status and European substantial equivalence designation for food applications, making it suitable for fortifying a wide range of nutritional foods and beverages.

In the nutritional supplement space, Mara supplies DHA as a cognitive and mental health ingredient, positioning its products for brain health, neurological support, and general wellness formulations. For food and beverage manufacturers, the company offers great-tasting Omega-3 oils formulated to meet the growing demand for DHA-enriched consumer products, including heart-health-focused foods.

Mara also serves the animal nutrition sector, with research demonstrating that animals fed its algal-derived Omega-3 products can produce naturally enriched eggs and meat, supporting improved Omega-3 PUFA levels in human consumers. Clinical trial data backs these claims, including a large randomized controlled trial examining the cardiovascular effects of consuming Omega-3-enriched chicken and eggs.

The company's research and development capabilities underpin its innovation pipeline, with a focus on advancing sustainable algae-based biotechnologies. By sourcing from microalgae rather than fish, Mara addresses both supply chain sustainability concerns and the growing consumer preference for marine-contaminant-free, plant-derived nutritional ingredients.